Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection. Academic Article uri icon

abstract

  • Background: Combination antiretroviral therapy has significantly advanced HIV-1 infection treatment. However, HIV-1 remains persistent in the brain; the inaccessibility of the blood-brain barrier allows for persistent HIV-1 infections and neuroinflammation. Nanotechnology-based drug carriers such as nanodiscoidal bicelles can provide a solution to combat this challenge. Methods: This study investigated the safety and extended release of a combination antiretroviral therapy drug (tenofovir)-loaded nanodiscs for HIV-1 treatment in the brain both in vitro and in vivo. Result: The nanodiscs entrapped the drug in their interior hydrophobic core and released the payload at the desired location and in a controlled release pattern. The study also included a comparative pharmacokinetic analysis of nanodisc formulations in in vitro and in vivo models. Conclusion: The study provides potential applications of nanodiscs for HIV-1 therapy development.

published proceedings

  • Nanomedicine (Lond)

author list (cited authors)

  • Garcia, C. R., Rad, A. T., Saeedinejad, F., Manojkumar, A., Roy, D., Rodrigo, H., ... Roy, U.

citation count

  • 3

complete list of authors

  • Garcia, Caroline R||Rad, Armin T||Saeedinejad, Farnoosh||Manojkumar, Arvind||Roy, Deepa||Rodrigo, Hansapani||Chew, Sue Anne||Rahman, Ziyaur||Nieh, Mu-Ping||Roy, Upal

publication date

  • January 2022